UBS Group
CYTK icon

UBS Group’s Cytokinetics CYTK Stock Holding History

UBS Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,900
Closed -$1.64M – 10540
2026
Q1 		$1.64M Buy
+24,900
New +$1.58M ﹤0.01% 5145
2025
Q4 		– Sell
-19,800
Closed -$1.09M – 10609
2025
Q3 		$1.09M Buy
+19,800
New +$816K ﹤0.01% 5504
2024
Q4 		– Sell
-600
Closed -$31.7K – 10001
2024
Q3 		$31.7K Buy
+600
New +$33.4K ﹤0.01% 7102
2024
Q1 		– Sell
-73,000
Closed -$6.09M – 9418
2023
Q4 		$6.09M Buy
+73,000
New +$2.64M ﹤0.01% 2562

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's CYTK Position: Q2 2026 in Review

UBS Group reduced its Cytokinetics (CYTK) stake by 44% in Q2 2026, selling an estimated $65.1M and leaving 1,171,287 shares worth $99.8M. The position accounts for 0.01% of the portfolio, ranked #1120.

UBS Group first reported a position in CYTK in Q4 2014 and has held it in 47 quarters since. The position peaked at $137M in Q1 2026. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • UBS Group held 1,171,287 shares of Cytokinetics worth $99.8M as of Q2 2026.
  • UBS Group sold 905,990 Cytokinetics shares in Q2 2026, an estimated $65.1M.
  • Cytokinetics made up 0.01% of UBS Group's portfolio in Q2 2026, its #1120 holding.
  • UBS Group first reported a position in Cytokinetics in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Cytokinetics position peaked at $137M in Q1 2026.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.